These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8330466)

  • 1. Uricosuric effect of CGS-12970, a new thromboxane synthase inhibitor.
    Saris SD; Piraino AJ; Morgan JM; Hirschhorn WL; Meidl E; Schaffer AV
    Clin Pharmacol Ther; 1993 Jul; 54(1):65-9. PubMed ID: 8330466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a specific thromboxane synthetase inhibitor on thromboxane generation and excretion in healthy dogs.
    Longhofer SL; Johnson HC; Culham CA; Schultz KT; Grauer GF
    Am J Vet Res; 1990 Nov; 51(11):1746-50. PubMed ID: 2240799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of CGS 12970 and inhibition of thromboxane synthesis after oral administration in healthy adults.
    Martin LL; Schaffer AV; Piraino A; Linberg L; Singh K; Rakhit A; Douglas FL
    Clin Pharmacol Ther; 1991 Apr; 49(4):433-41. PubMed ID: 2015733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent uricosuric effect of ambroxol.
    Oosterhuis B; Storm G; Cornelissen PJ; Su CA; Sollie FA; Jonkman JH
    Eur J Clin Pharmacol; 1993; 44(3):237-41. PubMed ID: 8491237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of the uricosuric action of the anti-inflammatory drug E3040 used to treat inflammatory bowel disease I: study using a rat model of hyperuricemia.
    Yamada H; Kotaki H; Furitsu H; Sawada Y; Iga T
    Biopharm Drug Dispos; 1999 Mar; 20(2):77-83. PubMed ID: 10206322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
    Shen Z; Gillen M; Miner JN; Bucci G; Wilson DM; Hall JW
    Drug Des Devel Ther; 2017; 11():2077-2086. PubMed ID: 28744099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uricosuric effect of different doses of irtemazole in normouricaemic subjects.
    Gresser U; Kamilli I; Kronawitter U; Zöllner N
    Eur J Clin Pharmacol; 1990; 38(5):489-91. PubMed ID: 2379534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity.
    Smith SR; Kubacki VB; Rakhit A; Martin LL; Schaffer AV; Jasani MK; Hefty DJ; Johnston T; Cannon C; Bennett WM
    Transplantation; 1993 Dec; 56(6):1422-6. PubMed ID: 8279014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase inhibitory and uricosuric activities of FK366 in healthy volunteers.
    Kanamaru M; Uematsu T; Nagashima S; Mizuno A; Terakawa M; Sugiyama A; Nakashima M
    J Clin Pharmacol; 1993 Nov; 33(11):1122-31. PubMed ID: 8300896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uricosurics and xanthine oxidase inhibitors: a single-dose assay.
    McMahon FG
    Curr Ther Res Clin Exp; 1970 Jun; 12(6):414-7. PubMed ID: 4987349
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypouricemic action of scopoletin arising from xanthine oxidase inhibition and uricosuric activity.
    Ding Z; Dai Y; Wang Z
    Planta Med; 2005 Feb; 71(2):183-5. PubMed ID: 15729630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
    Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
    Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the thromboxane synthesis inhibitor CGS-12970 on experimental acute renal allograft rejection.
    Mangino MJ; Brunt EM; Von Doersten P; Anderson CB
    J Pharmacol Exp Ther; 1989 Jan; 248(1):23-8. PubMed ID: 2643702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
    Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
    Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitor.
    Taniguchi T; Ashizawa N; Matsumoto K; Iwanaga T; Saitoh K
    J Pharm Pharmacol; 2016 Jan; 68(1):76-83. PubMed ID: 26589240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of the uricosuric action of E3040, a drug used to treat inflammatory bowel disease II: study using DBA/2N mice.
    Yamada H; Kotaki H; Furitsu H; Sawada Y; Iga T
    Biopharm Drug Dispos; 1999 Jul; 20(5):271-6. PubMed ID: 10594872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity.
    Smith SR; Creech EA; Schaffer AV; Martin LL; Rakhit A; Douglas FL; Klotman PE; Coffman TM
    Kidney Int; 1992 Jan; 41(1):199-205. PubMed ID: 1593856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben.
    Butler KD; Butler PA; Shand RA; Ambler J; Wallis RB
    Thromb Res; 1987 Mar; 45(6):751-61. PubMed ID: 3109067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uricosuric effects of niridazole.
    Weintraub M; Nash TE; Ottesen E; Becker MA
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):568-72. PubMed ID: 913024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.